Your shopping cart is currently empty

XX-650-23 is a small molecule CREB inhibitor that blocks the critical interaction between CREB and its required coactivator, CBP (CREB-binding protein), inducing apoptosis and cell cycle arrest in AML cells, and can be used in the study of acute myelogenous leukaemia (AML).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | In Stock | In Stock | |
| 5 mg | $93 | In Stock | In Stock | |
| 10 mg | $148 | In Stock | In Stock | |
| 25 mg | $297 | In Stock | In Stock | |
| 50 mg | $497 | In Stock | In Stock | |
| 100 mg | $693 | - | In Stock | |
| 500 mg | $1,450 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock | In Stock |
| Description | XX-650-23 is a small molecule CREB inhibitor that blocks the critical interaction between CREB and its required coactivator, CBP (CREB-binding protein), inducing apoptosis and cell cycle arrest in AML cells, and can be used in the study of acute myelogenous leukaemia (AML). |
| Targets&IC50 | AML cells:870 nM-2.3 μM |
| In vitro | During split Renilla luciferase complementation analysis, XX-650-23 exhibited an IC50 of 3.20 ± 0.43 μM in inhibiting the interaction between CREB and CBP [1]. Following treatment with XX-650-23 (100 pM - 10 μM) for 48 hours, four AML cell lines showed IC50 values ranging from 870 nM to 2.3 μM, defined as a 50% reduction in viable cell count compared to DMSO-treated cells, indicating the inhibition of AML growth by XX-650-23 [1]. |
| In vivo | XX-650-23 (2.3 mg/kg, intravenous injection) extends the survival of AML mouse model (NSG mice) and exhibits no toxicity[1]. |
| Synonyms | XX65023, XX 650 23 |
| Molecular Weight | 288.3 |
| Formula | C18H12N2O2 |
| Cas No. | 117739-40-9 |
| Smiles | N#CC1=CC=C(C=C1)NC(=O)C2=CC=3C=CC=CC3C=C2O |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (277.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (11.45 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.